KOD - Kodiak Sciences Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.80
-0.31 (-1.55%)
As of 9:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close20.11
Open20.07
Bid0.00 x 1800
Ask24.29 x 800
Day's Range19.56 - 20.07
52 Week Range5.65 - 21.25
Volume3,957
Avg. Volume197,283
Market Cap731.18M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Trade prices are not sourced from all markets
  • PR Newswire

    Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data from its ongoing Phase 1b study of its investigational therapy KSI-301 in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). The results were presented by Charles C. Wykoff, M.D, Ph.D., a clinical investigator in the study, as an oral presentation at the "First-Time Results of Clinical Trials" session of the American Academy of Ophthalmology Annual Meeting's Retina Subspecialty Day.

  • PR Newswire

    Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301

    PALO ALTO, Calif. , Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate ...

  • PR Newswire

    Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration

    PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak's anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with treatment-naïve wet (neovascular) age-related macular degeneration (AMD). "Treating the first patients in this pivotal study is an important step for Kodiak as we grow the company and accelerate our efforts with KSI-301," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "On World Sight Day, we recognize that patients with wet AMD often need frequent eye injections of an anti-VEGF medication to preserve their vision.

  • PR Newswire

    Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

    PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that Charles C. Wykoff, M.D., Ph.D., will present first-time results at the Annual Meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California. The Retina Subspecialty Day (October 11 – 12) will feature a presentation of emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-related macular degeneration (wet AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).

  • Disappointed by WeWork? Check Out These IPO Stocks.
    InvestorPlace

    Disappointed by WeWork? Check Out These IPO Stocks.

    For loyal followers of Matt McCall's "Moneyline" podcast, you'll notice a callback in this week's episode. Early in September, he warned investors to stay away from the WeWork IPO, and boy, was he right. In the last few weeks, the company delayed and then cancelled its IPO. Why? Allegations of co-founder Adam Neumann's drug use and company management took over headlines. Just this morning, WeWork announced it would cut as much as 25% of its workforce.So then how do you invest safely in IPO stocks? McCall urges investors to do "boots-on-the-ground" research to get a better feel for a company. He also warns listeners not to get distracted by a CEO's charisma or long, flowing hair. Using that research, he put together a list of compelling IPO stocks from 2019.While Beyond Meat (NASDAQ:BYND) stock has performed well this year, it doesn't make the list. Instead look to lesser-known names. Kodiak Sciences (NASDAQ:KOD), Palomar Holdings (NASDAQ:PLMR) and Yeti (NYSE:YETI) are some of his top picks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? What's different about these picks? They're "real" companies that will make shareholders money. On the flip side, WeWork might have been a great stock to talk about at bars, but it's a losing play. McCall's PodcastIPO stocks aren't the only thing McCall has advice on. In this week's episode of "Moneyline," he's back to his soothing words on the state of the stock market today. As rumors of a global recession and an ending bull market soar, he maintains that we've got at least one rally left.How does he determine this? Well, he looks at all that's bad and good in the investing world right now. The U.S.-China trade war, talks of President Donald Trump's impeachment and an ongoing UAW strike against General Motors (NYSE:GM) are weighing the market down. But a supportive Federal Reserve and low rates of unemployment are big positives. Plus, as McCall says, if the White House can be slightly less manic, there's huge upside ahead.Oh, and you've probably heard the news that Interactive Brokers (IEX:IBKR) led the trend of online brokers offering commission-free trading. In recent days, Charles Schwab (NYSE:SCHW), E*Trade (NASDAQ:ETFC) and TD Ameritrade (NASDAQ:AMTD) have joined its ranks. Is this a sure sign that online brokers are doomed? No. Listen in for more information on what this means, how Robinhood is involved and how you can turn this news into a great retirement savings opportunity.Tune in to Matt McCall's "Moneyline" podcast to learn more about all this, and above all else, remember not to panic next time you turn on the news.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best ETFs for 2019: The Race Is a Little More Gnarly Now * 7 Next-Generation Healthcare Stocks to Buy * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? The post Disappointed by WeWork? Check Out These IPO Stocks. appeared first on InvestorPlace.

  • PR Newswire

    Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

    Late-breaking results support Kodiak's objective of every three-, four-, and five-month long-interval dosing of KSI-301 in patients with wet AMD KSI-301 continues towards its development goals of demonstrating ...

  • PR Newswire

    Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting

    PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that updated data from the clinical development program for its investigational therapy KSI-301 will be presented at The Retina Society Annual Meeting on September 15 in London, U.K. "Developing intravitreal medicines with meaningfully differentiated durability has been Kodiak's objective since our founding one decade ago. Kodiak's announcement at this weekend's Retina Society Annual Meeting takes us another step closer to providing a transformative new therapeutic option to patients.  I believe KSI-301 has the potential to be a first-line anti-VEGF agent for patients suffering from retinal vascular diseases," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.

  • PR Newswire

    Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference

    PALO ALTO, Calif. , Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • PR Newswire

    Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

    PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France. "We continue to be pleased with the promising efficacy and safety data of KSI-301," said Victor Perlroth, M.D., Kodiak's Chief Executive Officer. "At EURETINA, we will report on outcomes with over 100 patients dosed and a growing safety database with over 250 injections of KSI-301.

  • Kodiak Sciences Inc. (NASDAQ:KOD) Insiders Increased Their Holdings
    Simply Wall St.

    Kodiak Sciences Inc. (NASDAQ:KOD) Insiders Increased Their Holdings

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • PR Newswire

    Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights

    PALO ALTO, Calif. , Aug. 14, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • PR Newswire

    Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference

    PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting
    PR Newswire

    Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting

    - Antibody Biopolymer Conjugates are a new scientific approach and design platform for ophthalmic intravitreal drugs - KSI-301 continues to achieve its development goals of demonstrating efficacy and safety ...

  • Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting
    PR Newswire

    Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting

    PALO ALTO, Calif., July 24, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical study will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual Meeting being held from July 26 – 30 in Chicago, IL.

  • Kodiak Sciences' Shares March Higher, Can It Continue?
    Zacks

    Kodiak Sciences' Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Kodiak Sciences.

  • Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue?
    Zacks

    Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Kodiak Sciences Inc. (KOD).

  • Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference
    PR Newswire

    Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference

    PALO ALTO, Calif. , May 30, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • How Much Of Kodiak Sciences Inc. (NASDAQ:KOD) Do Insiders Own?
    Simply Wall St.

    How Much Of Kodiak Sciences Inc. (NASDAQ:KOD) Do Insiders Own?

    Every investor in Kodiak Sciences Inc. (NASDAQ:KOD) should be aware of the most powerful shareholder groups...

  • PR Newswire

    Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights

    PALO ALTO, Calif. , May 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019
    PR Newswire

    Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019

    PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting
    PR Newswire

    Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting

    PALO ALTO, Calif., April 25, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, being held from April 28 – May 2 in Vancouver, Canada. "The clinical and preclinical data being presented at ARVO's Annual Meeting provide early evidence of the safety and efficacy of Kodiak's novel antibody biopolymer conjugates. It's exciting to see the preclinical science and thoughtful design underlying our ABC Platform begin to translate into clinical utility with our Phase 1 study of KSI-301, an anti-VEGF ABC being developed as a new and potentially better therapy for the most prevalent retinal vascular diseases like wet AMD, diabetic eye disease and retinal vein occlusion.

  • PR Newswire

    Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

    PALO ALTO, Calif. , March 28, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • PR Newswire

    Kodiak Sciences to Present at the Barclays Global Healthcare Conference

    PALO ALTO, Calif. , March 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble
    Zacks

    The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble

    The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble